Oxford Biomedica (NASDAQ:OXBDF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “

Shares of Oxford Biomedica (NASDAQ OXBDF) traded down 6.400% during midday trading on Wednesday, hitting $0.117. The company had a trading volume of 3,000 shares. The stock has a 50 day moving average price of $0.12 and a 200 day moving average price of $0.12. Oxford Biomedica has a 1-year low of $0.04 and a 1-year high of $0.15. The firm’s market capitalization is $361.33 million.

COPYRIGHT VIOLATION WARNING: “Oxford Biomedica (OXBDF) Downgraded to “Hold” at Zacks Investment Research” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/10/oxford-biomedica-oxbdf-downgraded-to-hold-at-zacks-investment-research.html.

Oxford Biomedica Company Profile

Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.

Get a free copy of the Zacks research report on Oxford Biomedica (OXBDF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.